Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer
Cancers · 05.08.2026 · 18 (15) · 2505
DOI: 10.3390/cancers18152505 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.08.2026. Verfasst von Blackberrie Eddins und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH, National Cancer Institute Training.
Abstract (Originalsprache)
Background/Objectives: The majority of thyroid cancer patients are diagnosed with papillary thyroid cancer. A complete R0 resection significantly lowers cancer recurrence risk for high-risk papillary thyroid cancer but can be difficult to achieve because tumor margins are not easily visualized. The purpose of the present narrative review is to describe current work and future directions in fluorescence-guided thyroid cancer surgery.
Methods
PubMed and Google Scholar were used to identify 45 articles that focused on fluorescence labeling and imaging of thyroid cancer published through February 2026 using the search terms “thyroid cancer” AND (“fluorescence imaging,” OR “NIR imaging” OR “optical imaging”) OR “fluorescence guided thyroidectomy”. Standalone abstracts and publications not available in English were excluded.
Results
17 fluorescent probes were shown to visualize tumor margins and micrometastases, 3 probes were able to visualize nerves, and 2 probes targeted lymph nodes. Most studies were done using animal models. Two probes (EMI-137, which targets tumors, and bevonescein, which targets nerves) were tested in clinical trials with good safety profiles.
Conclusions
Several tumor-targeted fluorophores and optical imaging strategies have shown promise for thyroid cancer localization, margin assessment, lymph node evaluation, and nerve visualization; however, most remain preclinical, and clinical utility will require standardized dosing, imaging thresholds, safety assessment, and outcome-based validation with multicenter clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
- VA San Diego Healthcare System, La Jolla, CA 92161, USA.
- Department of Surgery, National Taiwan University Hospital, Taipei 100225, Taiwan.
- Department of Surgery, Ewha Womans University College of Medicine, Seoul 07804, Republic of Korea.
- Center for Inflammation Imaging, Department of Radiology, Massachusetts General Brigham and Harvard Medical School, Boston, MA 02115, USA.
- Department of Chemistry, Center of Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30302, USA.
ORCID-Profile: Hyungju Kwon, Homan Kang, Maged Henary, Satoshi Kashiwagi, Michael Bouvet
Förderung
- NCI NIH HHS
- NIH
- National Cancer Institute Training
Zitieren
APA
Eddins, B., Kuo, T. C., Kwon, H., Kang, H., Henary, M., Kashiwagi, S., Hoffman, R. M., & Bouvet, M. (2026). Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer. Cancers, 18(15), 2505. https://doi.org/10.3390/cancers18152505
Vancouver
Eddins B, Kuo TC, Kwon H, Kang H, Henary M, Kashiwagi S, et al. Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer. Cancers. 2026;18(15):2505. doi:10.3390/cancers18152505
BibTeX
@article{Eddins2026,
author = {Eddins, Blackberrie and Kuo, Ting-Chun and Kwon, Hyungju and Kang, Homan and Henary, Maged and Kashiwagi, Satoshi and Hoffman, Robert M and Bouvet, Michael},
title = {Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2505},
doi = {10.3390/cancers18152505}
}
EUVIMED